AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $257.63. The company's market cap stands at 455.25B, with a P/E ratio of 72.10 and a dividend yield of 2.68%.
During the trading session on 2026-09-11, AbbVie(ABBV) shares reached a daily high of $259.61 and a low of $253.92. At a current price of $257.63, the stock is +1.5% higher than the low and still -0.8% under the high.
Trading activity shows a volume of 1.86M, compared to an average daily volume of 4.18M.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
The stock's 52-week range extends from a low of $190.75 to a high of $267.47.
ABBV News
Abbvie (ABBV) announced an update on their ongoing clinical study. The AbbVie Inc. (ABBV) ECLIPSE study, officially titled “Randomized, Double-blind, Placebo-C...
AbbVie Inc. (NYSE:ABBV) shares are edging higher Friday morning following Thursday’s announcement of positive Phase 3 trial results for its menstrual migraine t...
Ipsen is debating on building a production site in the U.S., with plans the next big plant built will manufacture either its Dysport drug, a rival to AbbVie’s (...
Analyst ratings
75%
of 32 ratingsMore ABBV News
Key Points AbbVie is successfully transitioning its revenue base toward newer immunology drugs to offset the loss of patent protection for Humira. Novo Nordis...
AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from its Phase 3 LUNA clinical trial. The study assessed atogepant, an oral calcitonin gene-relate...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie is reporting new data from an observational eye study in adults with diabetic macular...
AbbVie (ABBV) announced positive topline results from the Phase 3 LUNA study, which evaluated atogepant, a calcitonin gene-related peptide, or CGRP, receptor an...
HSBC analyst Rajesh Kumar raised the firm’s price target on AbbVie (ABBV) to $315 from $300 and keeps a Buy rating on the shares. The firm adjusted targets in t...
Key Points AbbVie's business has proved resilient in recent years. Costco has what it takes to navigate its current challenges. Both stocks have impressive d...
Key Points Pharmaceutical giant AbbVie has a longer history of dividend growth than Pfizer. Pfizer faces greater exposure this decade to the loss of patent ex...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.